Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
190/433
Matches for
“Mortality”
-
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.
### Background Medical comorbidities and functional status limitations are determinants of mortality in…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
…The leading causes of mortality were cancer (31%) and cardiovascular-related death…
-
Management of the patient with SVR. Review
…liver complications, hepatocellular carcinoma and mortality. Additional benefits include reduced morbidity related…
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
…more cardiovascular events and higher mortality (Hazard ratio [95% CI]: 2.75…
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…
-
Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
…and 2012 were pre-included. Mortality status was obtained from physicians, hospitals…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.
-
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Acute hepatitis C virus infection remains a major health concern in human…
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
As of 2016, there is no evidence-based pathway to stratify the…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
### Background Non-invasive liver fibrosis scores have been proposed as alternatives to…
-
Noninvasive diagnosis in alcohol-related liver disease. Review
### Background Alcohol-related liver disease (ALD) represents a major cause of death…
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
…and liver-related morbidity and mortality. More expensive tests such as FibroTest…
-
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
### Background And Aims Chronic hepatitis C (HCV) is a liver disease affecting…
-
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
…linked to cardiometabolic morbidity and mortality. Low-grade inflammation, oxidative stress and…
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
Even though alcohol-related liver disease (ALD) is a major cause of…
-
Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study.
…A decision tree was constructed with associated 2-year mortality incorporating an…
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.
### Background/Aims To compare non-invasive biological liver fibrosis scores, as alternatives…
-
Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication
-
Non-invasive diagnosis and follow-up of portal hypertension.
…of liver-related morbidity and mortality. In patients at risk of chronic…
-
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
-
Assessment of liver fibrosis: noninvasive means.
Liver biopsy, owing to its limitations and risks, is an imperfect gold…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…
-
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.
…cause of liver morbidity and mortality worldwide. While a proportion of the…
-
Noninvasive evaluation of NAFLD.
A common clinical concern in patients with NAFLD is whether they have…
-
Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.
### Aim The objective of this study was to evaluate liver fibrosis using…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
…the risk of morbidity and mortality, current UK guidance recommends that biopsy…
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.
### Background Studies have demonstrated that coronary artery calcification on one hand and…
-
FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.
-
Non-invasive assessment of liver fibrosis: are we ready?
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.
### Background Liver disease is the third leading cause of mortality in patients…
-
Personalized management of cirrhosis by non-invasive tests of liver fibrosis.
…leading causes of morbidity and mortality worldwide. In recent years, the development…
-
Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
…of cirrhosis and liver-related mortality, but we lack serum markers to…
-
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…
-
Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
### Background Liver stiffness and non-invasive tests predict overall survival in chronic…
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
…95% of patients received prednisolone; and the 2-year mortality was 63…
-
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
FibroTest has been validated as a biomarker of fibrosis in patients with…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.
### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
### Background & Aims The first aim was to extend the validation of FibroTest…
-
[Prognosis assessment of alcoholic liver disease: how and why?].
…Hepatic histology is the main parameter that predicts morbidity and mortality in…
-
Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients.
Transient elastography (TE) is a noninvasive technique to evaluate liver fibrosis. We…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
…prognostic of liver morbidity and mortality in non-alcoholic fatty liver disease…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…
-
Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.
### Objective Studies have shown that patients with failing Fontan circulation may develop…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
### Background Mortality related to complications of cirrhosis is increasing in patients with…
-
Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.
### Background & Aims Data on liver fibrosis evolution and its involvement in liver…
-
Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.
### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.
### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…
-
Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.
### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…
-
Non-invasive evaluation of liver fibrosis in chronic hepatitis C.
…main causes of morbidity and mortality in patients with CHC. Liver biopsy…
-
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.
### Background/Aims The aim of this study was to compare the performance…
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…
-
American Association for the Study of the Liver
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication
FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…
-
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.
### Background Patients with cystic fibrosis (CF) have a relevant morbidity and mortality…
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
### Objective To determine practices among physicians in Canada for the assessment of…
-
Commentary: prognostication of chronic hepatitis B - are Fibrotest and Fibroscan the final answers? Authors' reply.
-
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
### Context Recently, it has been shown that an allele in the adiponutrin…
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
-
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.
Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…
-
Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
### Objectives To compare plasma antiretroviral concentrations in HIV-HCV co-infected and…
-
Non-invasive markers for hepatic fibrosis.
With great advancements in the therapeutic modalities used for the treatment of…
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
…associated with increased morbidity and mortality. Ursodeoxycholic acid (UDCA) may have antioxidant…
-
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication
### Background Since 1920, a decrease in serum cholesterol has been identified as…
-
Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.
### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver…
-
Liver fibrosis markers in alcoholic liver disease.
Alcohol is one of the main factors of liver damage. The evaluation…
-
Non-invasive diagnosis of hepatitis B virus-related cirrhosis.
…associated with significant morbidity and mortality worldwide. Twenty-three percent of patients…
-
Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.
In Egypt, as elsewhere, liver biopsy (LB) remains the gold standard to…
-
Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.
### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…
-
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
### Objectives Liver fibrosis in chronic hepatitis C is related to sex, age…
-
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…
-
Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?
Liver biopsy remains the gold standard for the evaluation of fibrosis despite…
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.
### Background Hepatic fibrosis is highly prevalent in individuals with Fontan circulation. FibroSure…
-
Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.
Non-invasive biomarkers have gained popularity for estimating fibrosis stage. In our…
-
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.
As an alternative to liver biopsy, an index of five biochemical markers…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics.
Fontan-palliated patients are at risk for the development of Fontan-associated…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…
-
Liver biopsy: the best standard...when everything else fails.
-
Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
### Background Due to common routes of transmission, HIV and HBV are frequently…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.
Changes in the liver and bile ducts observed in patients diagnosed with…
-
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
### Background Few data are available on chronic hepatitis C (CHC) in elderly…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.
### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…
-
Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
### Aim To compare noninvasive methods presently used for steatosis detection and quantification…
-
Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Review
### Background & Aims Chronic hepatitis B virus (HBV) infection accounts for 30%-50…
-
Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.
### Objective Chronic viral hepatitis B and C cause liver fibrosis, leading to…
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…
-
Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
### Background & Aims Recent findings in hepatitis C virus (HCV)-monoinfected patients have…
-
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.
### Background/Aims The aim was to identify a panel of biomarkers (AshTest…
-
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.
Patients with HIV have a proclivity to develop liver fibrosis, especially when…
-
Noninvasive assessment of portal hypertension in patients with cirrhosis.
Severe portal hypertension is responsible for complications and death. Although measurement of…
-
Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.
### Background Liver fibrosis is a sign of advanced liver disease and is…
-
Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.
Barriers to management of HCV in injection drug users are related to…
-
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
-
The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.
### Background The diagnosis of alcoholic liver diseases is based on the history…
-
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver…
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.
### Background Liver biopsy and virological end points are standard references for assessing…
-
Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.
### Introduction Identifying liver fibrosis is important to evaluate the severity of liver…
-
Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers.
### Objective The aim of our study was to assess the diagnostic performance…
-
Biomarkers of liver fibrosis.
Liver biopsy, due to its limitations and risks, is an imperfect gold…
-
Analytical variability of the Fibrotest proteins.
### Objectives The analytical variability of the Fibrotest (FT) parameters raises the issue…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.
### Background One of the unmet needs in patients with type 2 diabetes…
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
…prognostic markers of liver related mortality in patients with chronic hepatitis C…
-
Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…
-
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
### Aims To evaluate the application of the recently proposed recommendations by the…
-
The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.
…major causes of morbidity and mortality in the present day world. The…
-
FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.
### Background Noninvasive markers of liver fibrosis have not been extensively studied in…
-
The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.
### Background The Fib-4 index is a simple and inexpensive biomarker to…
-
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.
### Background And Aim To assess the clinical and economic outcomes of non…
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…
-
Retracted: Executive functions in chronic hepatitis C virus infected elderly patients.
-
Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.
Haemophilia is an entity, wherein the HCV infection rate is greater than…
-
Usefulness of acoustic radiation force impulse and fibrotest in liver fibrosis assessment after liver transplant.
### Unlabelled Background and rationale. Acoustic radiation force impulse (ARFI) is a non…
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
### Background & Objectives One of the multiple factors contributing to virological response in…
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.
### Objectives Extent of liver fibrosis is one of the most important factors…
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…
-
Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.
### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…
-
Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.
Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…
-
Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.
### Background Accurately staging hepatitis C virus (HCV)-related fibrosis is crucial for…
-
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.
### Background And Aims Primary prevention of variceal bleeding with beta-blockers improves…
-
Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.
The aim of this study was to evaluate the diagnostic values of…
-
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
### Background/Aims The hepatitis C virus (HCV) infection is important cause of…
-
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…
-
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
### Background In recent years noninvasive methods have been evaluated for the assessment…
-
Applicability and variability of liver stiffness measurements according to probe position.
### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
### Aims And Methods Several serum biomarkers such as FibroTest, aspartate transaminase-platelet…
-
A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.
BACKGROUND: Biochemical markers for liver fibrosis (FibroTest) and necroinflammatory features (ActiTest) are…
-
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
### Background & Aims The aim of this study was to determine the diagnostic…
-
Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.
### Background The development of esophageal varices is a late complication of chronic…
-
Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.
### Background The efficiency of transient elastography for the assessment of liver fibrosis…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…
-
Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.
### Objective Patients with short bowel syndrome (SBS) receiving long-term parenteral nutrition…
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.
### Background Progression of recurrent hepatitis C is accelerated in liver transplant recipients…
-
Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.
### Background Hepatitis B (HB) infection is common in Mali. However, there is…
-
Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.
### Introduction The purpose of this clinical trial was to determine in routine…
-
Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.
### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…
-
The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…
-
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
### Background The best technique to estimate portal hypertension (PHT) is to measure…
-
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.
### Background FibroTest (FT) is the most frequently used serum fibrosis marker and…
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…
-
Progression of liver fibrosis among injection drug users with chronic hepatitis C.
Although most hepatitis C virus (HCV) infections are acquired by injection drug…
-
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.
### Objectives Precise evaluation of the level of liver fibrosis is recommended in…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication
The aim was to assess the utility of FibroTest-ActiTest (FT-AT…
-
Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.
### Background & Aims Most liver transplant centres have discontinued the practice of protocol…
-
Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.
### Background Liver fibrosis, now assessed by liver biopsy or using non-invasive…
-
Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
### Background The childhood/adult-onset lysosomal acid lipase deficiency (LALD; late-onset…
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
### Background Our aim was to assess the natural history of liver fibrosis…
-
Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.
### Background Recent longitudinal studies have emphasised the prognostic value of noninvasive tests…
-
The non-invasive assessment of hepatic fibrosis.
Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…
-
Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication
### Background Systematic screening for liver fibrosis in heavy-drinking patients is a…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
### Background No blood test has been shown to be effective in the…
-
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…
-
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
Liver fibrosis and activity indexes were validated in patients infected by hepatitis…
-
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.
Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total…
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
Liver fibrosis is a common pathway leading to cirrhosis, which is the…
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…
-
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.
### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered the gold standard for assessing histologic lesions…
-
Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.
### Background Noninvasive tests are crucial for the management and follow-up of…
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.
### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
### Background Biopsy is the usual gold standard for liver steatosis assessment. The…
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…
-
[Biomarkers for liver fibrosis: advances, advantages and disadvantages].
Liver cirrhosis in Mexico is one of the most important causes of…
-
Ministère des Affaires Sociales et de la Santé Key publication
Showing the full result list. The page is server-rendered and not paginated.